Wollastonite

Wollastonite (40 mg; intrathoracic administration; single dose) induces pleural sarcomas with variable incidence in female Osborne-Mendel rats^[2].
Wollastonite (10 mg/m³; administered via inhalation; 6 hours per day, 5 days per week; for 12 or 24 months) induces mild interstitial fibrosis in male F344 rats, but does not increase their pulmonary tumor incidence^[2].
Wollastonite (50-100 mg/m³; inhalation exposure; 6 hours per day; for 3 or 5 consecutive days) induces transient and milder pulmonary inflammatory responses in male Crl:CDBR rats compared with Crocidolite^[2].
Wollastonite (25 mg; intratracheal administration; single dose) induces mild to moderate pulmonary effects in male Wistar rats^[2].
Wollastonite (1 mg; intratracheal administration; single dose) induces mild, non-progressive chronic interstitial inflammation in male Sprague-Dawley rats within 6 months^[2].
Wollastonite (114 mg/m³; exposed via inhalation; 6 hours per day for 5 consecutive days) has a retention half-life of less than 1 week in male Crl:CDBR rats, indicating that it can be rapidly cleared from the lungs^[2].
Wollastonite-based scaffolds doped with dilute magnesium (CSi-Mgx) fabricated via 3D printing (surgical implantation; single administration) exhibit excellent strength, degradability and osteogenic capacity, rendering them promising for bone regeneration of thin-wall bone defects in rabbits^[3].
Wollastonite-hydroxyapatite composite biomaterial (surgical implantation; single administration) safely enhances vascularization and promotes new bone formation at the surgical defect site of the femur in rats at 12 weeks post-implantation^[3].